CIK 0001878313 · Pharmaceutical Preparations (SIC 2834) · NYSE · incorporated in DE · fiscal year ends 12/31
| FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|
| Revenue (USD) | 0 | 0 | 0 | |
| Net income (USD) | -22.4 M | |||
| Diluted EPS (USD/shares) | -0.7 | -1.49 | -1.75 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-10-07 | 424B3 | 424B3 | |
| 2026-10-06 | EFFECT | EFFECT items ,, | |
| 2026-10-06 | 8-K | 8-K items 7.01,9.01 | 2026-10-06 |
| 2026-10-02 | 4 | PRIMARY DOCUMENT | 2026-09-30 |
| 2026-10-02 | 4 | PRIMARY DOCUMENT | 2026-09-30 |
| 2026-10-02 | 4 | PRIMARY DOCUMENT | 2026-09-30 |
| 2026-10-02 | 4 | PRIMARY DOCUMENT | 2026-09-30 |
| 2026-10-02 | 4 | PRIMARY DOCUMENT | 2026-09-30 |
| 2026-10-02 | 424B3 | 424B3 | |
| 2026-10-02 | 4 | PRIMARY DOCUMENT | 2026-09-30 |
| 2026-09-25 | S-3 | S-3 | |
| 2026-09-15 | 4 | PRIMARY DOCUMENT | 2026-09-14 |
| 2026-09-14 | 4 | PRIMARY DOCUMENT | 2026-09-10 |
| 2026-09-01 | 4 | PRIMARY DOCUMENT | 2026-08-26 |
| 2026-08-28 | EFFECT | EFFECT items ,, | |
| 2026-08-26 | 4 | PRIMARY DOCUMENT | 2026-08-24 |
| 2026-08-24 | 4 | PRIMARY DOCUMENT | 2026-08-20 |
| 2026-08-21 | S-3 | S-3 | |
| 2026-08-14 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-08-10 | 10-Q | 10-Q | 2026-06-30 |
| 2026-07-02 | 4 | PRIMARY DOCUMENT | 2026-06-30 |
| 2026-07-02 | 4 | PRIMARY DOCUMENT | 2026-06-30 |
| 2026-07-02 | 4 | PRIMARY DOCUMENT | 2026-06-30 |
| 2026-07-02 | 4 | PRIMARY DOCUMENT | 2026-06-30 |
| 2026-07-02 | 4 | PRIMARY DOCUMENT | 2026-06-30 |
Forms on file (last 1,000): 4 231, 8-K 109, CORRESP 25, 10-Q 13, 3 12, 424B5 11, UPLOAD 11, S-1/A 9. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=MAIA (0.002 USD), /gw/filings/filings?ticker=MAIA&form=8-K, /gw/filings/facts?ticker=MAIA&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange